Who are R2: Lenalidomide + ixazomib maintenance's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/r2-lenalidomide-ixazomib-maintenance.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

R2: Lenalidomide + ixazomib maintenance — Competitive Intelligence Brief

R2: Lenalidomide + ixazomib maintenance (R2: Lenalidomide + ixazomib maintenance) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Immunomodulatory agent + proteasome inhibitor combination. Area: Oncology.

phase 3 Immunomodulatory agent + proteasome inhibitor combination Cereblon (lenalidomide); 20S proteasome (ixazomib) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

R2: Lenalidomide + ixazomib maintenance (R2: Lenalidomide + ixazomib maintenance) — University of Leeds. Lenalidomide and ixazomib work together as immunomodulatory and proteasome inhibitor agents to enhance anti-myeloma immune responses and suppress tumor cell proliferation in multiple myeloma maintenance therapy.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
R2: Lenalidomide + ixazomib maintenance TARGET	R2: Lenalidomide + ixazomib maintenance	University of Leeds	phase 3	Immunomodulatory agent + proteasome inhibitor combination	Cereblon (lenalidomide); 20S proteasome (ixazomib)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Immunomodulatory agent + proteasome inhibitor combination class)

University of Leeds · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). R2: Lenalidomide + ixazomib maintenance — Competitive Intelligence Brief. https://druglandscape.com/ci/r2-lenalidomide-ixazomib-maintenance. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab